S-1: Aptevo Secures $60M Equity Line, Faces Dilution Risks

Aptevo Therapeutics entered a $60 million standby equity purchase agreement with YA II PN, LTD., registering shares for resale while advancing its cancer immunotherapy pipeline.

Summary

• Aptevo Therapeutics Inc., a clinical-stage biotechnology company, has entered into a Standby Equity Purchase Agreement (Purchase Agreement) with YA II PN, LTD. (YA) on January 8, 2026.
• Under the Purchase Agreement, YA has committed to purchase up to $60.0 million of Aptevo's common stock at Aptevo's discretion over a 36-month period.
• Aptevo is registering 7,075,471 shares of common stock for resale by YA under this prospectus, but will not receive direct proceeds from YA's sales. Aptevo will receive proceeds from its sales to YA under the Purchase Agreement.
• The purchase price for shares sold to YA will be 96% of the lowest of the three daily Volume Weighted Average Prices (VWAPs) during a pricing period.
• Aptevo paid a $25,000 structuring fee and will pay a 2.00% commitment fee (approximately $1.2 million) to YA, payable in five equal quarterly installments.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol APVO, with a last reported sale price of $8.26 per share on January 27, 2026.
• Aptevo has undergone two reverse stock splits recently: 1-for-20 on May 23, 2025, and 1-for-18 on December 29, 2025.
• The company reported a net loss of $(21,640) thousand for the nine months ended September 30, 2025, and $(24,130) thousand for the year ended December 31, 2024.
• Clinical candidate mipletamig, a CD123xCD3 T cell engager, is being evaluated in the Phase 1b/2 RAINIER study for frontline Acute Myelogenous Leukemia (AML), with Phase 1b results to date showing "highly favorable" safety and efficacy.
• Clinical candidate ALG.APV-527 is in a dose escalation trial for multiple solid tumor types.
• Aptevo maintains two wholly-owned platform technologies, ADAPTIR and ADAPTIR-FLEX, for developing novel immunotherapy candidates.

Sentiment

Score: 3

Explanation: The filing indicates significant financial challenges and high dilution risk, despite some positive early clinical data. The continuous need for capital raises through dilutive instruments and repeated reverse stock splits reflect a precarious financial position and ongoing concerns about Nasdaq listing compliance. While the clinical pipeline shows promise, the immediate financial outlook and shareholder value impact are negative.

Positives

• Secured a commitment for up to $60.0 million in equity financing through the Standby Equity Purchase Agreement with YA, providing potential capital for operations and development.
• Clinical candidate mipletamig has shown "highly favorable" safety and efficacy results in cohorts 1, 2, and 3 of the ongoing Phase 1b RAINIER study for frontline AML.
• The company has a robust pipeline with two clinical candidates (mipletamig, ALG.APV-527) and six preclinical candidates (APVO603, APVO711, APVO442, APVO452, APVO451, APVO455).
• Wholly owns two versatile platform technologies, ADAPTIR and ADAPTIR-FLEX, enabling efficient design of novel immunotherapy molecules.
• Regained compliance with Nasdaq's minimum shareholders' equity requirement by July 1, 2025, after raising approximately $15.9 million in equity capital.

Negatives

• The equity purchase agreement with YA poses a risk of "substantial dilution" to existing stockholders, as the 7,075,471 shares registered for resale represent approximately 922% of the 767,164 shares outstanding as of September 30, 2025.
• The company has incurred significant net losses, reporting $(21,640) thousand for the nine months ended September 30, 2025, and $(24,130) thousand for the year ended December 31, 2024, indicating ongoing operational losses.
• The company has a history of non-compliance with Nasdaq listing requirements, having received a notification for failing to meet the minimum shareholders' equity requirement in May 2025, and has conducted two reverse stock splits (1-for-20 in May 2025 and 1-for-18 in December 2025) to maintain compliance.
• There is a risk of immediate delisting from Nasdaq if the common stock bid price drops below $1.00 per share for 30 consecutive business days, due to having conducted a reverse stock split in the past year.
• The actual amount of proceeds from the YA agreement is uncertain and depends on market conditions and the company's discretion, potentially being less than the $60.0 million commitment.
• The resale of a significant amount of shares by YA, or the perception of such sales, could depress the market price of the common stock and increase volatility.
• The company has been, and may in the future be, subject to short selling strategies that could drive down the market price of its common stock.

Risks

• It is not possible to predict the actual number of shares sold under the Purchase Agreement or the actual gross proceeds received, as sales depend on market conditions and other factors.
• Limitations in the Purchase Agreement, including the 9.99% Ownership Limitation for YA and the 19.99% Exchange Cap (unless stockholder approval is obtained or average price exceeds $8.753), could prevent the company from raising the full $60.0 million.
• Any issuance and sale of a substantial amount of common stock under the Purchase Agreement could cause additional substantial dilution to stockholders.
• The resale by YA of a significant amount of shares, or the perception of such sales, could cause the market price of common stock to decline and be highly volatile.
• Broad discretion in the use of net proceeds from the Purchase Agreement, which may not be used effectively, potentially leading to financial losses and delays in product development.
• Investors buying shares at different times from YA will likely pay different prices and may experience different levels of dilution and investment outcomes.
• Future sales and issuances of common stock or other securities might result in significant dilution and could cause the price of common stock to decline.
• Risk of delisting from the Nasdaq Capital Market if the company does not maintain compliance with listing requirements, such as the minimum $1.00 bid price or $2.5 million in shareholders' equity.
• The company may be subject to short selling strategies that could drive down the market price of its common stock.
• The company's ability to continue as a going concern is a risk factor.
• Failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of common stock.
• Inability to become profitable.
• Inability to maintain and establish collaborations or obtain additional funding.
• Inability to obtain regulatory approval of current and future drug candidates.
• Inability to secure sufficient funding and alternative sources of funding on favorable terms.
• The success of clinical development activities, clinical trials, and research and development programs is uncertain.
• Inability to retain key employees, consultants, and advisors.
• Inability to obtain, maintain, protect, and enforce sufficient intellectual property rights.
• Impact of legislative, regulatory, or policy changes.
• Adverse impact from macroeconomic conditions, including inflation, cost of capital, and changes in economic policies and regulations.

Future Outlook

The company intends to use any net proceeds from the Standby Equity Purchase Agreement for working capital, funding clinical programs, advancing new programs, business development activities, and general corporate purposes. The actual amount of proceeds is uncertain and depends on market conditions. The company is focused on the continued development of its pipeline products, including advancing clinical candidates mipletamig and ALG.APV-527, and progressing its preclinical assets. Maintaining Nasdaq listing compliance remains a focus, with a stockholder meeting scheduled to approve share issuances to YA in excess of the Exchange Cap.

Management Comments

• We believe we are skilled at candidate generation, validation, and subsequent preclinical and clinical development.
• We expect that any proceeds received by us from such sales of shares under the Purchase Agreement will be used for continued development of our pipeline products, as well as the advancement of new programs, business development activities, and general corporate purposes.

Industry Context

Aptevo Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on novel immunotherapy candidates for cancer. The development of bispecific and multi-specific antibody candidates using proprietary platforms like ADAPTIR and ADAPTIR-FLEX aligns with a broader industry trend towards precision oncology and targeted immune modulation. The company's strategy to drive tumor-specific immune activation while limiting systemic toxicity is a key differentiator in the field. However, as a clinical-stage company with significant net losses, it faces common industry challenges related to funding R&D, navigating regulatory approvals, and managing cash burn, which is underscored by its reliance on equity financing agreements and past struggles with Nasdaq listing compliance. The high dilution potential from the YA agreement is a common characteristic of early-stage biotech companies seeking to fund extensive development pipelines.

Comparison to Industry Standards

• The company's reliance on a Standby Equity Purchase Agreement (SEPA) for financing is a common strategy for smaller, clinical-stage biotechnology companies that have limited revenue streams and require significant capital for research and development. This method, while providing access to capital, often comes with substantial dilution risks, which is typical for companies in this stage compared to more established pharmaceutical firms.
• The reported "highly favorable" safety and efficacy results for mipletamig in Phase 1b for AML are positive early indicators, but a full assessment against industry benchmarks would require more detailed clinical data, including response rates, duration of response, and overall survival, compared to existing AML treatments like venetoclax + azacitidine combinations or other CD123-targeting therapies in development (e.g., Xencor's vibecotamab, MacroGenics' flotetuzumab).
• The company's repeated reverse stock splits (1-for-20 and 1-for-18 within a year) and past non-compliance with Nasdaq's minimum shareholders' equity requirement indicate financial distress and challenges in maintaining market capitalization, which is a red flag compared to financially stable industry peers.
• The development of ADAPTIR and ADAPTIR-FLEX platforms for bispecific and multi-specific antibodies is in line with cutting-edge oncology research, similar to efforts by companies like Amgen (BiTE platform), Regeneron (VelocImmune), and Genmab (DuoBody), which are actively developing next-generation immune-engaging therapies. Aptevo's ability to generate five CD3-engaging molecules with a low cytokine release profile suggests a focus on improving the therapeutic index, a critical aspect in T-cell engager development.

Corporate Governance

Related Party Transactions

• The Standby Equity Purchase Agreement with YA II PN, LTD. involves YA as a selling stockholder and a significant financial partner. YA is considered an underwriter within the meaning of Section 2(a)(11) of the Securities Act.
• YA II PN, LTD. is affiliated with a registered broker-dealer, which may be used to effectuate sales of shares and receive customary commissions.

Stakeholder Impact

• Shareholders: Face significant potential dilution from the issuance of up to 7,075,471 shares under the YA Purchase Agreement, representing approximately 922% of current outstanding shares. The market price of shares could decline due to future sales by YA and the perception of such sales. Existing shareholders' economic and voting interests will be diluted.
• Employees: Continued funding from the YA agreement could support ongoing research and development, potentially stabilizing employment and advancing career opportunities within the company's pipeline programs.
• Customers/Patients: Continued development of immunotherapy candidates, particularly mipletamig and ALG.APV-527, could lead to new treatment options for cancer patients, especially those with AML and solid tumors.
• Creditors: The capital raise provides additional liquidity, which could improve the company's ability to meet its financial obligations, though ongoing losses suggest continued financial risk.
• Suppliers: Continued operations and R&D activities would likely maintain demand for supplies and services.

Next Steps

• Hold a special meeting of stockholders on February 18, 2026, to approve the issuance and sale of shares of common stock to YA in excess of the Exchange Cap.
• Continue the Phase 1b/2 RAINIER study for mipletamig in frontline AML patients.
• Continue the dose escalation trial for ALG.APV-527 in multiple solid tumor types.
• Advance preclinical candidates APVO603, APVO711, APVO442, APVO452, APVO451, and APVO455.
• Utilize proceeds from the YA Purchase Agreement for working capital, clinical programs, new program advancement, business development, and general corporate purposes.
• Monitor and maintain compliance with Nasdaq's continued listing requirements, particularly the minimum bid price.

Key Dates

Recommendation

The filing reveals a company in a highly precarious financial state. The need for a $60 million standby equity purchase agreement, following a previous $25 million agreement, underscores persistent capital requirements. The potential for "substantial dilution" is extreme, with the registered shares for resale representing over 900% of currently outstanding shares. This level of dilution, combined with a history of significant net losses, two recent reverse stock splits, and ongoing Nasdaq listing compliance issues (including the risk of immediate delisting if the bid price falls below $1.00), points to severe downward pressure on the stock price and significant risk to shareholder value. While early clinical data for mipletamig is positive, the financial instability and the highly dilutive nature of the financing mechanism overshadow any clinical progress for a seasoned investor. The company's ability to continue as a going concern is explicitly mentioned as a risk. Investors should consider exiting their positions to avoid further capital erosion.

Keywords

Aptevo Therapeutics, APVO, Biotechnology, Immunotherapy, Cancer Treatment, SEC Filing, S-1, Standby Equity Purchase Agreement, YA II PN LTD, Equity Financing, Dilution, Nasdaq Listing, Reverse Stock Split, Clinical Trials, Mipletamig, AML, ALG.APV-527, Solid Tumors, ADAPTIR Platform, ADAPTIR-FLEX Platform, Oncology, Drug Development, Capital Raise